(Q28290363)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18691982%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

review article

1 reference

title

Clinically relevant pharmacokinetic drug interactions with second-generation antidepressants: an update (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18691982%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18691982%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

author name string

Vincenza Santoro

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18691982%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

Concetta D'Arrigo

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18691982%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

language of work or name

English

0 references

publication date

1 July 2008

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18691982%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

published in

Clinical Therapeutics

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18691982%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

volume

30

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18691982%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

page(s)

1206-1227

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18691982%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

issue

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18691982%20AND%20SRC:MED&resulttype=core&format=json

Selective serotonin reuptake inhibitors versus tricyclic antidepressants: a meta-analysis of efficacy and tolerability.

12 January 2020

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980047-1

7 January 2021

What is the meaning of treatment resistant/refractory major depression (TRD)? A systematic review of current randomized trials

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980047-1

7 January 2021

Newer antidepressants and the cytochrome P450 system

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980047-1

7 January 2021

Pharmacokinetic drug interaction potential of selective serotonin reuptake inhibitors.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980047-1

7 January 2021

Pharmacokinetics of selective serotonin reuptake inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980047-1

7 January 2021

Selective serotonin reuptake inhibitors and cytochrome P-450 mediated drug-drug interactions: an update

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980047-1

7 January 2021

Metabolic drug interactions with new psychotropic agents.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980047-1

7 January 2021

Comparisons of catalytic selectivity of cytochrome P450 subfamily enzymes from different species

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980047-1

7 January 2021

P450 superfamily: update on new sequences, gene mapping, accession numbers and nomenclature.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980047-1

7 January 2021

Pharmacogenetics and adverse drug reactions

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980047-1

7 January 2021

Inhibition and induction of cytochrome P450 and the clinical implications

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980047-1

7 January 2021

Selective serotonin reuptake inhibitors and CNS drug interactions. A critical review of the evidence

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980047-1

7 January 2021

The AGNP-TDM expert group consensus guidelines: therapeutic drug monitoring in psychiatry

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980047-1

7 January 2021

Clinically significant drug interactions with antidepressants in the elderly.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980047-1

7 January 2021

The effect of selective serotonin re-uptake inhibitors on cytochrome P4502D6 (CYP2D6) activity in human liver microsomes

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980047-1

7 January 2021

Inhibition of CYP2C9 by selective serotonin reuptake inhibitors in vitro: studies of phenytoin p-hydroxylation

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980047-1

7 January 2021

The effects of selective serotonin reuptake inhibitors and their metabolites on S-mephenytoin 4'-hydroxylase activity in human liver microsomes

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980047-1

7 January 2021

Inhibition of human cytochrome P450-3A isoforms by fluoxetine and norfluoxetine: in vitro and in vivo studies

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980047-1

7 January 2021

Elevated antidepressant plasma levels after addition of fluoxetine

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980047-1

7 January 2021

Fluoxetine-induced tricyclic toxicity: extent and duration

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980047-1

7 January 2021

Quantification and mechanism of the fluoxetine and tricyclic antidepressant interaction

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980047-1

7 January 2021

Serum concentrations of clozapine and its major metabolites: effects of cotreatment with fluoxetine or valproate

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980047-1

7 January 2021

Serum levels of clozapine and norclozapine in patients treated with selective serotonin reuptake inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980047-1

7 January 2021

Effect of fluoxetine on the plasma concentrations of clozapine and its major metabolites in patients with schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980047-1

7 January 2021

Inhibition of risperidone metabolism by fluoxetine in patients with schizophrenia: a clinically relevant pharmacokinetic drug interaction

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980047-1

7 January 2021

The effect of fluoxetine on the pharmacokinetics and safety of risperidone in psychotic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980047-1

7 January 2021

Effect of fluoxetine and imipramine on the pharmacokinetics and tolerability of the antipsychotic quetiapine

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980047-1

7 January 2021

Metabolic drug interactions with newer antipsychotics: a comparative review.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980047-1

7 January 2021

The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980047-1

7 January 2021

Fluoxetine impairs clearance of alprazolam but not of clonazepam

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980047-1

7 January 2021

Increased carbamazepine plasma concentrations after fluoxetine coadministration

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980047-1

7 January 2021

Carbamazepine coadministration with fluoxetine or fluvoxamine

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980047-1

7 January 2021

Toxic reaction following the combined administration of fluoxetine and phenytoin: two case reports

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980047-1

7 January 2021

Fluoxetine-warfarin interaction

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980047-1

7 January 2021

Antidepressant interactions with warfarin

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980047-1

7 January 2021

Fluoxetine impairs the CYP2D6-mediated metabolism of propafenone enantiomers in healthy Chinese volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980047-1

7 January 2021

Interaction of metoprolol and fluoxetine

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980047-1

7 January 2021

Heart block in a patient on propranolol and fluoxetine

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980047-1

7 January 2021

Fluoxetine-associated potentiation of calcium-channel blockers

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980047-1

7 January 2021

Inhibition by paroxetine of desipramine metabolism in extensive but not in poor metabolizers of sparteine

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980047-1

7 January 2021

Desipramine pharmacokinetics when coadministered with paroxetine or sertraline in extensive metabolizers

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980047-1

7 January 2021

Mirtazapine and paroxetine: a drug-drug interaction study in healthy subjects.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980047-1

7 January 2021

Paroxetine potentiates the central nervous system side effects of perphenazine: contribution of cytochrome P4502D6 inhibition in vivo.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980047-1

7 January 2021

Plasma concentrations of risperidone and 9-hydroxyrisperidone during combined treatment with paroxetine

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980047-1

7 January 2021

Dose-dependent interaction of paroxetine with risperidone in schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980047-1

7 January 2021

Plasma concentrations of clozapine and its major metabolites during combined treatment with paroxetine or sertraline

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980047-1

7 January 2021

Pharmacokinetic interactions of clozapine with selective serotonin reuptake inhibitors: differential effects of fluvoxamine and paroxetine in a prospective study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980047-1

7 January 2021

No influence of the antidepressant paroxetine on carbamazepine, valproate and phenytoin

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980047-1

7 January 2021

Effect of potent CYP2D6 inhibition by paroxetine on atomoxetine pharmacokinetics

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980047-1

7 January 2021

Paroxetine, a cytochrome P450 2D6 inhibitor, diminishes the stereoselective O-demethylation and reduces the hypoalgesic effect of tramadol

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980047-1

7 January 2021

Clinically significant drug interactions with cholinesterase inhibitors: a guide for neurologists

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980047-1

7 January 2021

Fluvoxamine is a potent inhibitor of cytochrome P4501A2

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980047-1

7 January 2021

Fluvoxamine-tricyclic antidepressant interaction

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980047-1

7 January 2021

Effect of fluvoxamine on the pharmacokinetics of imipramine and desipramine in healthy subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980047-1

7 January 2021

Inhibition of antidepressant demethylation and hydroxylation by fluvoxamine in depressed patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980047-1

7 January 2021

Fluvoxamine augmentation increases serum mirtazapine concentrations three- to fourfold

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980047-1

7 January 2021

Fluvoxamine Inhibition and Carbamazepine Induction of the Metabolism of Clozapine

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980047-1

7 January 2021

Addition of low-dose fluvoxamine to low-dose clozapine monotherapy in schizophrenia: drug monitoring and tolerability data from a prospective clinical trial

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980047-1

7 January 2021

Fluvoxamine increases plasma and urinary levels of clozapine and its major metabolites in a time- and dose-dependent manner

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980047-1

7 January 2021

Clozapine and fluvoxamine, a curious complexity

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980047-1

7 January 2021

Fluvoxamine-Clozapine Drug Interaction: Inhibition In Vitro of Five Cytochrome P450 Isoforms Involved in Clozapine Metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980047-1

7 January 2021

Fluvoxamine but not sertraline inhibits the metabolism of olanzapine: evidence from a therapeutic drug monitoring service

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980047-1

7 January 2021

Interaction of olanzapine with fluvoxamine

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980047-1

7 January 2021

Fluvoxamine augmentation of olanzapine in chronic schizophrenia: pharmacokinetic interactions and clinical effects

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980047-1

7 January 2021

Effect of fluvoxamine on plasma risperidone concentrations in patients with schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980047-1

7 January 2021

A pharmacokinetic and pharmacodynamic evaluation of the combined administration of alprazolam and fluvoxamine.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980047-1

7 January 2021

Inhibition of diazepam metabolism by fluvoxamine: a pharmacokinetic study in normal volunteers.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980047-1

7 January 2021

Interaction between carbamazepine and fluvoxamine

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980047-1

7 January 2021

Fluvoxamine and fluoxetine do not interact in the same way with the metabolism of the enantiomers of methadone.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980047-1

7 January 2021

Influence of the CYP1A2 inhibitor fluvoxamine on tacrine pharmacokinetics in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980047-1

7 January 2021

Low daily 10-mg and 20-mg doses of fluvoxamine inhibit the metabolism of both caffeine (cytochrome P4501A2) and omeprazole (cytochrome P4502C19).

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980047-1

7 January 2021

Increased bioavailability of oral melatonin after fluvoxamine coadministration.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980047-1

7 January 2021

Interaction between fluvoxamine and cotinine or caffeine

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980047-1

7 January 2021

Toxic Interaction Between Fluvoxamine and Sustained Release Theophylline in an 11-Year-Old Boy

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980047-1

7 January 2021

Fluvoxamine-induced theophylline toxicity

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980047-1

7 January 2021

Fluvoxamine. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic efficacy in depressive illness

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980047-1

7 January 2021

Human cytochromes mediating sertraline biotransformation: seeking attribution

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980047-1

7 January 2021

CYP2D6 inhibition in patients treated with sertraline.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980047-1

7 January 2021

The effect of sertraline on the pharmacokinetics of desipramine and imipramine

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980047-1

7 January 2021

Effect of sertraline on plasma nortriptyline levels in depressed elderly

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980047-1

7 January 2021

Plasma risperidone concentrations during combined treatment with sertraline.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980047-1

7 January 2021

Dose-response evaluation of the interaction between sertraline and alprazolam in vivo.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980047-1

7 January 2021

Clonazepam and sertraline: absence of drug interaction in a multiple-dose study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980047-1

7 January 2021

Lack of sertraline efficacy probably due to an interaction with carbamazepine

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980047-1

7 January 2021

Lamotrigine toxicity secondary to sertraline

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980047-1

7 January 2021

Concurrent administration of donepezil HCl and sertraline HCl in healthy volunteers: assessment of pharmacokinetic changes and safety following single and multiple oral doses

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980047-1

7 January 2021

Coadministration of sertraline with cisapride or pimozide: an open-label, nonrandomized examination of pharmacokinetics and corrected QT intervals in healthy adult volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980047-1

7 January 2021

Citalopram and desmethylcitalopram in vitro: human cytochromes mediating transformation, and cytochrome inhibitory effects.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980047-1

7 January 2021

Tricyclic antidepressant plasma levels after augmentation with citalopram: a case study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980047-1

7 January 2021

Non-response to citalopram in depressive patients: pharmacokinetic and clinical consequences of a fluvoxamine augmentation

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980047-1

7 January 2021

Fluoxetine augmentation in citalopram non-responders: pharmacokinetic and clinical consequences

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980047-1

7 January 2021

Citalopram causes no significant alterations in plasma neuroleptic levels in schizophrenic patients

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980047-1

7 January 2021

Co-administration of citalopram and clozapine: effect on plasma clozapine levels

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980047-1

7 January 2021

Lack of interaction between citalopram and the CYP3A4 substrate triazolam

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980047-1

7 January 2021

Lack of effect of citalopram on the steady-state pharmacokinetics of carbamazepine in healthy male subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980047-1

7 January 2021

Carbamazepine augmentation in depressive patients non-responding to citalopram: a pharmacokinetic and clinical pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980047-1

7 January 2021

Effect of citalopram on plasma levels of oral theophylline.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980047-1

7 January 2021

Investigation of multiple dose citalopram on the pharmacokinetics and pharmacodynamics of racemic warfarin.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980047-1

7 January 2021

Lack of effect of a single dose of ketoconazole on the pharmacokinetics of citalopram

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980047-1

7 January 2021

The clinical pharmacokinetics of escitalopram

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980047-1

7 January 2021

Comparison of duloxetine, escitalopram, and sertraline effects on cytochrome P450 2D6 function in healthy volunteers.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980047-1

7 January 2021

An evaluation of the potential for pharmacokinetic interaction between escitalopram and the cytochrome P450 3A4 inhibitor ritonavir

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980047-1

7 January 2021

The effect of cimetidine or omeprazole on the pharmacokinetics of escitalopram in healthy subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980047-1

7 January 2021

Venlafaxine oxidation in vitro is catalysed by CYP2D6.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980047-1

7 January 2021

O- and N-demethylation of venlafaxine in vitro by human liver microsomes and by microsomes from cDNA-transfected cells: effect of metabolic inhibitors and SSRI antidepressants

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980047-1

7 January 2021

Venlafaxine: in vitro inhibition of CYP2D6 dependent imipramine and desipramine metabolism; comparative studies with selected SSRIs, and effects on human hepatic CYP3A4, CYP2C9 and CYP1A2.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980047-1

7 January 2021

Venlafaxine and metabolites are very weak inhibitors of human cytochrome P450-3A isoforms

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980047-1

7 January 2021

Effect of venlafaxine on imipramine metabolism

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980047-1

7 January 2021

Pharmacokinetic and pharmacodynamic evaluation of the potential drug interaction between venlafaxine and diazepam.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980047-1

7 January 2021

Diphenhydramine alters the disposition of venlafaxine through inhibition of CYP2D6 activity in humans

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980047-1

7 January 2021

Duloxetine is both an inhibitor and a substrate of cytochrome P4502D6 in healthy volunteers

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980047-1

7 January 2021

Duloxetine hydrochloride: a new dual-acting medication for the treatment of major depressive disorder

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980047-1

7 January 2021

Mirtazapine in combination with amitriptyline: a drug-drug interaction study in healthy subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980047-1

7 January 2021

Lack of drug interactions between mirtazapine and risperidone in psychiatric patients: a pilot study

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980047-1

7 January 2021

Lack of a pharmacokinetic interaction between mirtazapine and the newer antipsychotics clozapine, risperidone and olanzapine in patients with chronic schizophrenia.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980047-1

7 January 2021

Drug-drug interaction studies with mirtazapine and carbamazepine in healthy male subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980047-1

7 January 2021

Concomitant use of mirtazapine and phenytoin: a drug-drug interaction study in healthy male subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980047-1

7 January 2021

Clinical pharmacokinetics of reboxetine, a selective norepinephrine reuptake inhibitor for the treatment of patients with depression

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980047-1

7 January 2021

No effect of reboxetine on plasma concentrations of clozapine, risperidone, and their active metabolites.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980047-1

7 January 2021

Bupropion for major depressive disorder: Pharmacokinetic and formulation considerations

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980047-1

7 January 2021

Inhibition of CYP2D6 activity by bupropion

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980047-1

7 January 2021

Nortriptyline toxicity secondary to interaction with bupropion sustained-release

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980047-1

7 January 2021

Severe sinus bradycardia after initiation of bupropion therapy: a probable drug-drug interaction with metoprolol

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980047-1

7 January 2021

Carbamazepine but not valproate induces bupropion metabolism.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980047-1

7 January 2021

Lopinavir/ritonavir reduces bupropion plasma concentrations in healthy subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980047-1

7 January 2021

Human CYP3A4 and the metabolism of nefazodone and hydroxynefazodone by human liver microsomes and heterologously expressed enzymes

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980047-1

7 January 2021

Inhibition of cytochrome P450 by nefazodone in vitro: studies of dextromethorphan O- and N-demethylation

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980047-1

7 January 2021

Loratadine and terfenadine interaction with nefazodone: Both antihistamines are associated with QTc prolongation

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980047-1

7 January 2021

Nefazodone and cyp450 3a4 interactions with cyclosporine and tacrolimus1.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980047-1

7 January 2021

Myositis and rhabdomyolysis associated with concurrent use of simvastatin and nefazodone

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980047-1

7 January 2021

Rhabdomyolysis with simvastatin and nefazodone

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980047-1

7 January 2021

Coadministration of nefazodone and benzodiazepines: II. A pharmacokinetic interaction study with triazolam

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980047-1

7 January 2021

Coadministration of nefazodone and benzodiazepines: III. A pharmacokinetic interaction study with alprazolam

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980047-1

7 January 2021

Pharmacokinetic and Pharmacodynamic Interactions of Oral Midazolam with Ketoconazole, Fluoxetine, Fluvoxamine, and Nefazodone

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980047-1

7 January 2021

Investigation of pharmacokinetic and pharmacodynamic interactions after coadministration of nefazodone and haloperidol

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980047-1

7 January 2021

Increase in plasma levels of clozapine and norclozapine after administration of nefazodone.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980047-1

7 January 2021

Carbamazepine-nefazodone interaction in healthy subjects

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980047-1

7 January 2021

Increased use of antidepressants at the end of life: population-based study among people aged 65 years and above

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980047-1

7 January 2021

Evidence-based guidelines for the pharmacological treatment of anxiety disorders: recommendations from the British Association for Psychopharmacology

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980047-1

7 January 2021

Antidepressant drugs: prevalence, incidence and indication of use in general practice of Southern Italy during the years 2003-2004.

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980047-1

7 January 2021

Antidepressant-drug interactions are potentially but rarely clinically significant

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980047-1

7 January 2021

Detrimental antidepressant drug-drug interactions: are they clinically relevant?

1 reference

https://api.crossref.org/works/10.1016%2FS0149-2918%2808%2980047-1

7 January 2021

10.1016/S0149-2918(08)80047-1

Identifiers

DOI

2 references

Consolidated OpenCitations Corpus – April 2017

1590408

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18691982%20AND%20SRC:MED&resulttype=core&format=json

12 January 2020

1590408

1 reference

Consolidated OpenCitations Corpus – April 2017

Consolidated OpenCitations Corpus – April 2017

2 references

1590408